Crescent Biopharma, Inc.
CBIO
$17.14
$0.513.07%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -24.84M | -23.28M | -92.40M | -24.61M | -21.79M |
| Total Depreciation and Amortization | 66.00K | 64.00K | 54.00K | 28.00K | 2.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.30M | 4.21M | 84.84M | 2.08M | 7.55M |
| Change in Net Operating Assets | 3.01M | 10.07M | -19.24M | 4.96M | -2.16M |
| Cash from Operations | -19.46M | -8.94M | -26.74M | -17.54M | -16.40M |
| Capital Expenditure | -13.00K | -147.00K | -193.00K | -586.00K | -140.00K |
| Sale of Property, Plant, and Equipment | 1.77M | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | -8.00M | -72.00M | -- | -- |
| Cash from Investing | 1.76M | -8.15M | -72.19M | -586.00K | -140.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 280.00K | -- | 178.86M | -- | 144.28M |
| Repurchase of Common Stock | -- | -- | 0.00 | -1.25M | -177.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -144.00K | -6.95M | 0.00 | 0.00 | 2.76M |
| Cash from Financing | 136.00K | -6.95M | 178.86M | -1.25M | 146.86M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -17.57M | -24.03M | 79.93M | -19.38M | 130.32M |